Tag Archives: Krystal Biotech Inc

Krystal Biotech Inc (KRYS) Receives a Buy from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech Inc (KRYS – Research Report). The company’s shares closed last Monday at $42.20. According to TipRanks.com, Prasad is a 4-star analyst with an

Analysts Offer Insights on Healthcare Companies: Krystal Biotech Inc (NASDAQ: KRYS), Prevail Therapeutics Inc (NASDAQ: PRVL) and Intec Pharma Ltd (NASDAQ: NTEC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech Inc (KRYS – Research Report), Prevail Therapeutics Inc (PRVL – Research Report) and Intec Pharma Ltd (NTEC – Research Report). Krystal

Chardan Capital Believes Krystal Biotech Inc (NASDAQ: KRYS) Won’t Stop Here

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech Inc (KRYS – Research Report) today and set a price target of $75. The company’s shares opened today at $37.83, close to its 52-week high of $39.95. Amusa

Analysts Offer Insights on Healthcare Companies: Krystal Biotech Inc (NASDAQ: KRYS) and Applied Therapeutics Inc (NASDAQ: APLT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech Inc (KRYS – Research Report) and Applied Therapeutics Inc (APLT – Research Report) with bullish sentiments. Krystal Biotech Inc (KRYS)

H.C. Wainwright Keeps Their Buy Rating on Krystal Biotech Inc (KRYS)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech Inc (KRYS – Research Report), with a price target of $38. The company’s shares closed yesterday at $32. Pantginis said: “Valuation and risks

William Blair Keeps Their Buy Rating on Krystal Biotech Inc (KRYS)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech Inc (KRYS – Research Report). The company’s shares opened today at $31.05. Prasad said: “We continue to view the anticipated second quarter clinical